Additionally, the study evaluates the efficacy of the endothelin receptor antagonist bosentan in targeting EDN1 signaling to reverse chemoresistance and systematically validates the therapeutic potential of the EDN1/β-arr1/YAP axis as a combinatorial strategy to overcome chemotherapy resistance in CRC. The gene discussed is EDN1; the disease is colorectal carcinoma.